Rhumbline Advisers Chinook Therapeutics, Inc. Transaction History

Rhumbline Advisers

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$18.66 - $38.58 $139,408 - $288,231	7,471 Added 9.14%	89,242 $3.43 Million
Q1 2023 May 11, 2023	BUY	$21.53 - $26.8 $14,597 - $18,170	678 Added 0.84%	81,771 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $81,636 - $119,847	4,382 Added 5.71%	81,093 $2.13 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $233,128 - $311,148	13,314 Added 21.0%	76,711 $1.51 Million
Q2 2022 Aug 11, 2022	BUY	$12.59 - $18.8 $166,351 - $248,404	13,213 Added 26.33%	63,397 $1.11 Million
Q1 2022 May 12, 2022	BUY	$12.02 - $16.69 $52,431 - $72,801	4,362 Added 9.52%	50,184 $821,000
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $50,659 - $79,757	4,739 Added 11.54%	45,822 $747,000
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $19,492 - $25,187	1,695 Added 4.3%	41,083 $524,000
Q2 2021 Aug 05, 2021	BUY	$13.6 - $18.98 $317,424 - $442,993	23,340 Added 145.44%	39,388 $556,000
Q1 2021 May 06, 2021	SELL	$14.17 - $19.11 $10,910 - $14,714	-770 Reduced 4.58%	16,048 $249,000
Q4 2020 Feb 10, 2021	BUY	$11.9 - $20.91 $200,134 - $351,664	16,818 New	16,818 $267,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.